On the stock market since 2012, it operates in the world of health and science. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $18.9M in the vault; even if every debt were paid off, $18.9M would remain.
Over the last 12 months, company executives reported 36 buys and 0 sells. Management buying with its own money is usually read as a good sign.
It pays out $15.10 per share each year — regular cash for whoever holds the stock.
A loss of $1.2M against $0 in annual sales.
The price action doesn’t yet back an upward turn. Council score: 0/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
On our five-subject report card, MACK sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MACK is a high-risk stock — not yet profitable, and its future rides on its product catching on.